Compounds · Retatrutide · continued

Second pass at: Triple agonism: additive, synergistic, or neither? posts 121–121

Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

n.cabreraTL2 Moderator3 Oct 2025#121

a.zamora, post #29: How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population. Go to post

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

0 likes in reply to #29 10mo

Suggested topics

Topic	Participants	Replies	Views	Activity
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide retatrutide randomised trial effect size preprint Solved Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…	+10	14	8.4k	16h
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo
Retatrutide dose escalation in the published trials Compounds › Retatrutide preprint retatrutide effect size Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…	+149	159	30k	15mo
About the Retatrutide category Compounds › Retatrutide retatrutide TRIUMPH programme randomised trial Pinned Wiki Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…		4	12k	2y
Retatrutide mass and identity: what a report should show Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with STEP 4 ( JAMA , 2021)…	+22	27	872	22h

Related topics — sharing the tags TRIUMPH programme, effect size, retatrutide

Topic	Participants	Replies	Views	Activity
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Solved Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Comparing PIONEER 6 ( N Engl J Med ,…	+48	52	609	10mo
The "under review" status pill and when a moderator applies it Evidence › Preprints risk of bias effect size preprint Posting this under the heading it deserves: The "under review" status pill and when a moderator applies it Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read it…	+96	119	17k	3mo
How to read a phase 2 result without treating it as a phase 3 result — what changed since Compounds › Retatrutide TRIUMPH programme randomised trial preprint Solved Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it…	+25	35	568	6mo
Immortal time bias in a claims-database study — one year on Evidence › Study critique effect size risk of bias confounding Solved Posting this under the heading it deserves: Immortal time bias in a claims-database study — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SURMOUNT-1 (…	+41	46	3.7k	22h
Comparators chosen for regulatory reasons rather than clinical ones — one year on Evidence › Trials randomised trial intention to treat open label estimand Solved Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read…	+82	87	1.1k	12mo